Impact of ursodeoxycholic acid in IHCP cases

Effect of ursodeoxycholic acid on abnormal liver enzymes and their association with maternal and foetal outcomes in intrahepatic cholestasis of pregnancy - NILL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/063580

Enrollment

Registered

2024-03-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O364- Maternal care for intrauterine death

Interventions

Intervention1: URSODEOXYCHOLOC ACID GROUP: 150 mg BD orally till bile acid comes to normal Control Intervention1: Ursodeoxycholic acid: 300 mg BD orally till the bile acid level comes to normal

Eligibility

Inclusion criteria

Inclusion criteria: Singleton pregnant women with =20 weeks of gestation and having pruritis and serum bile acid of 10micromol/L or more.

Exclusion criteria

Exclusion criteria: 1. Multifetal pregnancies 2. Maternal/foetal heart disorders 3. Liver disorder: Hepatitis C, Hepatitis B, Cholelithiasis 4. Medication for any dermatological disease, which can cause itching

Design outcomes

Primary

Measure	Time frame
PRE TEST AND POST TEST OF LIVER ENZYME WILL BE DONETimepoint: Baseline, 2 weeks and time of delivery	—

Secondary

Measure	Time frame
NATimepoint: NA	—

Countries

India

Contacts

Public ContactNidhi

GD GOENKA UNIVERSITY

nidhilhmc1@gmail.com9958296439

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026